24 withdrawn. 24 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Withdrawn 24 |
| Phase 1 | 3 | Withdrawn 3 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders Buspirone - Autism Spectrum Disorder, Anxiety | Phase 2 | Withdrawn | Massachusetts General Hospital | 2024-12-01 | 2024-09-26 | |
| A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder JZP541, Placebo - Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2023-06-30 | 2024-11-08 | |
| Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges BPT/OST, Peer Support - ADHD | Phase 2 / Phase 3 | Withdrawn | Seattle Children's Hospital | 2022-05-18 | 2026-04-24 | |
| A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder Medical Grade Cannabis oil, Placebos - Autistic Disorder | Phase 2 | Withdrawn | TO Pharmaceuticals | 2020-09-01 | 2022-06-09 | |
| Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) CP101, Placebo - Autism Spectrum Disorder, Autism | Phase 2 | Withdrawn | Finch Research and Development LLC. | 2020-05-01 | 2021-04-08 | |
| VR for Joint Attention Support in ASD Floreo Joint Attention Module, Regularly Scheduled Therapy - Autism Spectrum Disorder | Phase 2 | Withdrawn | Floreo, Inc. | 2018-07-20 | 2019-07-17 | |
| Methylphenidate for Cocaine Dependence Methylphenidate Pill - Substance-Related Disorders | Phase 2 | Withdrawn | ANRS, Emerging Infectious Diseases | 2018-06-01 | 2018-07-20 | |
| Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology Bumetanide, Placebo - Autistic Disorder | Phase 2 | Withdrawn | University Hospital, Limoges | 2016-12-01 | 2026-06-09 | |
| Adipose Derived Stem Cell Therapy for Autism Fat Harvesting and Stem Cell Injection - Autism | Phase 1 / Phase 2 | Withdrawn | Ageless Regenerative Institute | 2016-10-01 | 2017-07-21 | |
| Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder Clonidine, Placebo (for clonidine) - Autism Spectrum Disorder | Phase 2 | Withdrawn | Ohio State University | 2016-08-01 | 2017-02-02 | |
| Cortical Metrics in Intervention Trials With Autism Spectrum Disorders Dextromethophan - Autism Spectrum Disorders | Phase 2 / Phase 3 | Withdrawn | Duke University | 2015-08-01 | 2016-08-25 | |
| A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome SNC-102 sustained release tablet - Tourette Syndrome | Phase 2 | Withdrawn | Synchroneuron Inc. | 2015-04-01 | 2021-04-13 | |
| An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder EPI-743 - Autism Spectrum Disorder | Phase 2 | Withdrawn | Edison Pharmaceuticals Inc | 2014-10-31 | 2022-01-21 | |
| Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder Methylphenidate Hydrochloride - Conduct Disorder, Attention Defict Hyperactivity Disorder | Phase 1 / Phase 2 | Withdrawn | National Institute of Mental Health (NIMH) | 2014-09-04 | 2019-12-03 | |
| Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium divalproex sodium, Placebo - Autism | Phase 2 | Withdrawn | Boston Children's Hospital | 2014-04-01 | 2016-10-21 | |
| Intranasal Oxytocin and Learning in Autism Syntocinon (synthetic oxytocin), Placebo - Autism Spectrum Disorders | Phase 2 | Withdrawn | University of Minnesota | 2014-03-01 | 2019-11-01 | |
| Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Deep brain stimulator ventral electrode up to 2 mA, Deep brain stimulator ventral electrode up to 3 mA, Deep brain stimulator dorsal electrode up to 2 mA - Tourette's Syndrome | Phase 1 / Phase 2 | Withdrawn | The University of Western Australia | 2013-03-01 | 2021-05-18 | |
| Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome PF-03654746, Placebo - Tourette's Syndrome | Phase 2 | Withdrawn | Pfizer | 2012-04-01 | 2019-04-01 | |
| Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders Buspirone, Placebo - Autism Spectrum Disorder (ASD) | Phase 2 | Withdrawn | Massachusetts General Hospital | 2011-11-01 | 2024-06-28 | |
| A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome Tetrabenazine MR, Placebo - Tourette's Syndrome | Phase 2 | Withdrawn | Bausch Health Americas, Inc. | 2011-03-01 | 2019-11-29 |
Showing 20 of 24. Sign in to see all of them.
Autism Spectrum Disorder (11) · Autistic Disorder (11) · Child Development Disorders, Pervasive (4) · Tourette Syndrome (4) · Attention Deficit Disorder with Hyperactivity (3) · Anxiety Disorders (2) · Tics (2) · Angelman Syndrome (1) · Asperger Syndrome (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Conduct Disorder (1) · Marijuana Abuse (1) · Mitochondrial Diseases (1) · Rett Syndrome (1) · Substance-Related Disorders (1)
Mental Disorders (24) · Child Development Disorders, Pervasive (12) · Autism Spectrum Disorder (5) · Central Nervous System Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Movement Disorders (5) · Nervous System Diseases (5) · Basal Ganglia Diseases (4) · Brain Diseases (4) · Neurodegenerative Diseases (4) · Tic Disorders (4) · Attention Deficit and Disruptive Behavior Disorders (3)
Buspirone (2) · Methylphenidate (2) · Valproic Acid (2) · Acamprosate (1) · Atomoxetine Hydrochloride (1) · Bumetanide (1) · Clonidine (1) · Fluoxetine (1) · HMGA2 Protein (1) · Lipectomy (1) · N-ethyl-3-fluoro-3-(3-fluoro-4-(pyrrolidinylmethyl)phenyl)cyclobutanecarboxamide (1) · Oxytocin (1) · Succimer (1) · alpha-tocotrienol quinone (1) · nabiximols (1)
National Institute of Mental Health (NIMH) (3) · Massachusetts General Hospital (2) · Pfizer (2) · ANRS, Emerging Infectious Diseases (1) · Ageless Regenerative Institute (1) · Assistance Publique - Hôpitaux de Paris (1) · Bausch Health Americas, Inc. (1) · Boston Children's Hospital (1) · Duke University (1) · Edison Pharmaceuticals Inc (1) · Finch Research and Development LLC. (1) · Floreo, Inc. (1) · Jazz Pharmaceuticals (1) · Ohio State University (1) · Seattle Children's Hospital (1)
United States (12) · France (2) · Australia (1) · Israel (1)
Amine Benyamina, Pr (1) · Atilla Ceranoglu, MD (1) · Barry S Fogel, MD (1) · Christopher Lind, FRACS (1) · Gagan Joshi, M.D. (1) · James J Blair, Ph.D. (1) · Lihi Bar-LEv (1) · Linmarie Sikich, MD (1) · Sarah Spence, MD PhD (1) · Sharon McQuillan, MD (1) · Suma Jacob, M.D. Ph.D (1)